An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

The enhanced steric and bonding influences exerted by iodide are not sufficient to perturb isostructurality in a series of ternary crystals that differ only in the halide substituent, i.e. X = Cl, Br and I.

Diorganotin(IV) compounds with the general formula R2SnL [H2L = (E)-N'-[1-(5-nitro-2-hydroxybenzylidene]-3-hydroxy-2-naphthohydrazide; R = Me (1.toluene and 1), n-Bu (2), Ph (3), Cy (4), Bz (5), o-ClBz (6) and p-ClBz (7)] have been synthesised and characterised by elemental analyses, IR, H-1, C-13{1H} and 119Sn NMR spectros-copy, thermal analysis and in the cases of 1 and 3, single crystal X-ray diffraction. Crystallography, in accord with NMR, indicate highly distorted penta-coordinate geometries whereby each C2NO2 donor set is defined by the NO2 donor atoms derived from di-anionic L and two tin-bound organo substituents. The Schiff base ligand and the corresponding diorganotin compounds have been evaluated against two colon human carcinoma cell lines (HT-29 and HCT 116) and a normal colon fibroblast cell line (CCD-18Co). Among the evaluated compounds, the n-butyl derivative, 2, is most potent and least toxic to the cancer and normal cell lines, respectively, yielding the highest safety profile (high SI). In addition, the anti-bacterial activities have been evaluated against a panel of 21 Gram positive and Gram negative bacteria. Based on the broth dilution method, non-toxic 3, exhibited promising anti-bacterial effects against two Gram positive bacteria, namely, Enterococcus faecalis and Staphylo-coccus epidermidis.

The X-ray crystal structure determination of the glutaric acid-amide derivative, 4-ClC6H4N(H)C(=O)(CH2)3C(=O)OH (1), is described. The backbone of the molecule adopts an extended, all-trans configuration but the terminal carboxylic acid and phenyl resides are twisted out of the plane through the bridging atoms, as seen in the torsion angles of O(carboxylic acid)–C(m)–C(m)–C(m) [13.9(5)°] and C(m)–N–C(p)–C(p) [47.1(4)°]; m = methylene and p = phenyl. The most striking feature of the molecular packing is the formation of supramolecular tapes mediated by carboxylic acid-O–H⋯O(carbonyl) and amide-N–H⋯O(amide) hydrogen bonding.

Abstract C48H38As2Cl4O2Sn, monoclinic, P21/n (no. 14), a = 10.8019(1) Å, b = 14.6976(1) Å, c = 13.6266(1) Å, β = 90.983(1)°, V = 2163.07(3) Å3, Z = 2, R gt (F) = 0.0199, wR ref (F2) = 0.0514, T = 100 K.

Abstract C14H14Cl2Sn, orthorhombic, P212121 (no. 19), a = 8.2912(1) Å, b = 9.6221(1) Å, c = 18.5616(2) Å, V = 1480.82(3) Å3, Z = 4, R gt (F) = 0.0142, wR ref (F 2) = 0.0347, T = 100 K.

Abstract C26H28ClO2P, monoclinic, P21/c (no. 14), a = 11.6061(2) Å, b = 19.7791(4) Å, c = 11.1982(3) Å, β = 116.278(3)°, V = 2304.98(10) Å3, Z = 4, R gt (F) = 0.0373, wR ref (F 2) = 0.1034, T = 100 K.

Stabilising C–Cl(lone-pair)⋯π(chelate ring) interactions are described.

Abstract C18H26Cl2O2S2Sn, monoclinic, P21/n (no. 14), a = 8.3295(1) Å, b = 10.5647(1) Å, c = 12.0078(1) Å, β = 96.612(1)°, V = 1049.642(18) Å3, Z = 2, R gt (F) = 0.0174, wR ref(F 2) = 0.0455, T = 100 K.

C12H8Cl4Sn, monoclinic, P21/c (no. 14), a = 13.4238(1) Å, b = 18.2079(2) Å, c = 5.7617(1) Å, β = 95.506(1)°, V = 1401.77(3) Å3, Z = 4, R gt(F) = 0.0272, wR ref(F 2) = 0.0798, T = 100 K.

Abstract C25H23Br2Cl3N2Sn, monoclinic, P21/c (no. 14), a = 10.9372(1) Å, b = 23.1045(1) Å, c = 11.1856(1) Å, β = 106.942(1)°, V = 2703.91(4) Å3, Z = 4, R gt (F) = 0.0167, wR ref(F 2) = 0.0393, T = 100 K.

Abstract C22H16Cl4N2Sn, monoclinic, P21/n (no. 14), a = 10.0393(1) Å, b = 14.4490(2) Å, c = 14.1502(2) Å, β = 92.846(1)°, V = 2050.07(5) Å3, Z = 4, R gt (F) = 0.0224, wR ref (F 2) = 0.0590, T = 100 K.

Abstract C14H14Br2Sn, monoclinic, P21/c (no. 14), a = 12.9848(2) Å, b = 18.9911(2) Å, c = 6.0550(1) Å, β = 99.136(1)°, V = 1474.19(4) Å3, Z = 4, R gt (F) = 0.0193, wR ref (F2) = 0.0490, T = 100 K.

C22H16Cl4N2Sn, monoclinic, P2(1)/n (no. 14), a = 10.0393(1) angstrom, b = 14.4490(2) angstrom, c = 14.1502(2) angstrom, beta = 92.846(1)degrees, V = 2050.07(5) angstrom(3), Z = 4, R-gt(F) = 0.0224, wR(ref) (F-2) = 0.0590, T = 100 K.

C 38 H 26 Cl 2 Mo 2 N 6 O 10 , triclinic, P 1̄ (no. 2), a = 7.7151(2) Å, b = 10.5336(2) Å, c = 12.5668(2) Å, α = 73.027(2)°, β = 76.226(2)°, γ = 72.269(2)°, V = 917.83(4) Å 3 , Z = 1, R gt ( F ) = 0.0234, wR ref ( F 2 ) = 0.0612, T = 100(2) K.

C16H25FN2O4S2Sn, monoclinic, P21/n (no. 14), a = 11.2227(1) Å, b = 12.6793(1) Å, c = 13.8731(1) Å, β = 98.282(1)°, V = 1953.50(3) Å3, Z = 4, Rgt(F) = 0.0198, wRref(F2) = 0.0507, T = 100(2) K.

C24H22ClNOSn, monoclinic, P21/c (no. 14), a = 13.7584(1) Å, b = 13.5542(1) Å, c = 13.0912(1) Å, β = 115.778(1)°, V = 2198.36(3) Å3, Z = 4, Rgt(F) = 0.0170, wRref(F2) = 0.0448, T = 100(2) K.